US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Super League Gaming Inc.

4.03

-0.3000-6.93%

Post-market: 3.97-0.0599-1.49%19:59 EDT

Volume:342.08K

Turnover:1.45M

Market Cap:8.05M

PE:-0.33

High:4.44

Open:4.28

Low:3.99

Close:4.33

52wk High:137.16

52wk Low:2.12

Shares:2.00M

Float Shares:1.65M

Volume Ratio:0.02

T/O Rate:20.78%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-12.3857

EPS(LYR):-40.4307

ROE:-503.98%

ROA:-64.67%

PB:0.62

PE(LYR):-0.10

Loading ...

Overview Company News Filings

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE

InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability

Press Release: Super League Issues Letter Encouraging Shareholders to Vote in Support of the Misfits Ads Division Acquisition

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Super League Acquires Stake in Top Roblox Experience, My Avatar!

THOMSON REUTERS

Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026

Super League Enterprise price target lowered to $15 from $60 at Maxim

3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease

InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock Upside

Benzinga_recent_news

Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings Summary

Super League FY2025 net loss widens 24.51% to $20.7 million; revenue drops 29.91% to $11.3 million

Press Release: Super League Reports Fourth Quarter and Full Year 2025 Financial Results, Completes Business Transformation and Advances Path to Profitability

Super League Enterprise Inc expected to post a loss of $3.28 a share - Earnings Preview

Super League to buy Misfits Ads Division for USD 1.5 million and 19.99% equity stake

Press Release: Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Super League to acquire Misfits Ads Division for USD 1.5 million and 19.99% equity stake

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/SLE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":4.03,"timestamp":1787342400000,"preClose":4.33,"halted":0,"volume":342082,"hourTrading":{"tag":"盘后","latestPrice":3.9701,"preClose":4.03,"latestTime":"19:59 EDT","volume":9923,"amount":39762.1622,"timestamp":1787356781233,"change":-0.0599,"changeRate":-0.014864,"amplitude":0.029429},"delay":0,"changeRate":-0.06928406466512697,"floatShares":1646352,"shares":1997600,"eps":-12.385672,"marketStatus":"Market Closed","change":-0.3,"latestTime":"08-21 16:00:00 EDT","open":4.28,"high":4.4362,"low":3.99,"amount":1446237.1755000001,"amplitude":0.103048,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-12.385672,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":4.33,"preHourTrading":{"tag":"盘前","latestPrice":4.3,"preClose":4.33,"latestTime":"09:29 EDT","volume":20499,"amount":87961.885467,"timestamp":1787318983394,"change":-0.03,"changeRate":-0.006928,"amplitude":0.083072},"postHourTrading":{"tag":"盘后","latestPrice":3.9701,"preClose":4.03,"latestTime":"19:59 EDT","volume":9923,"amount":39762.1622,"timestamp":1787356781233,"change":-0.0599,"changeRate":-0.014864,"amplitude":0.029429},"volumeRatio":0.02282414046556692},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":1646352,"roa":"-64.67%","roe":"-503.98%","lyrEps":-40.430703,"volumeRatio":0.02282414046556692,"shares":1997600,"dividePrice":0,"high":4.4362,"amplitude":0.103048,"preClose":4.33,"low":3.99,"week52Low":2.12,"pbRate":"0.62","psRate":"0.69","week52High":137.16,"institutionHeld":0,"latestPrice":4.03,"eps":-12.385672,"divideRate":0,"volume":342082,"delay":0,"ttmEps":-12.385672,"open":4.28,"prevYearClose":7.326,"prevWeekClose":2.27,"prevMonthClose":2.66,"prevQuarterClose":2.97,"fiveDayClose":2.27,"twentyDayClose":2.66,"sixtyDayClose":3.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"SLE","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-2.7},{"market":"US","date":"2026-05-15","symbol":"SLE","fiscalQuarterEnding":"2026/03","expectedEps":-2.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-1.77},{"market":"US","date":"2026-03-27","symbol":"SLE","fiscalQuarterEnding":"2025/12","expectedEps":-3.12,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774584000000,"reportTimeType":"pre","actualEps":-9.44},{"market":"US","date":"2026-01-23","symbol":"SLE","defaultRemindTime":1769178600000,"type":"split","dateTimestamp":1769144400000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2025-11-13","symbol":"SLE","fiscalQuarterEnding":"2025/09","expectedEps":-2.83,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-2.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1782792000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2026-08-21","current":-0.325376,"percent":0.342697,"low":-0.738945,"twenty":-0.347244,"median":-0.26748,"eighty":-0.210977,"high":-0.044016,"avg":-0.281117,"sd":0.1162,"marketCap":6506742},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-04","current":-0.234475,"twenty":-0.342935,"median":-0.283459,"eighty":-0.210567,"marketCap":3900496},{"date":"2025-04-11","current":-0.236161,"twenty":-0.340036,"median":-0.28231,"eighty":-0.212359,"marketCap":3928533},{"date":"2025-04-17","current":-0.236161,"twenty":-0.338893,"median":-0.280718,"eighty":-0.213857,"marketCap":3928533},{"date":"2025-04-25","current":-0.369736,"twenty":-0.338893,"median":-0.280836,"eighty":-0.213857,"marketCap":6150554},{"date":"2025-05-02","current":-0.394848,"twenty":-0.347107,"median":-0.282596,"eighty":-0.213857,"marketCap":6568294},{"date":"2025-05-09","current":-0.347723,"twenty":-0.34901,"median":-0.284084,"eighty":-0.213899,"marketCap":5784365},{"date":"2025-05-16","current":-0.174182,"twenty":-0.348716,"median":-0.282596,"eighty":-0.211859,"marketCap":2897515},{"date":"2025-05-23","current":-0.187657,"twenty":-0.347631,"median":-0.280836,"eighty":-0.209762,"marketCap":2928392},{"date":"2025-05-30","current":-0.243307,"twenty":-0.347723,"median":-0.280836,"eighty":-0.209995,"marketCap":3796802},{"date":"2025-06-06","current":-0.252949,"twenty":-0.347265,"median":-0.280718,"eighty":-0.210038,"marketCap":3947265},{"date":"2025-06-13","current":-0.226363,"twenty":-0.347212,"median":-0.28021,"eighty":-0.210038,"marketCap":3532387},{"date":"2025-06-20","current":-0.204904,"twenty":-0.346791,"median":-0.280097,"eighty":-0.210029,"marketCap":3197521},{"date":"2025-06-27","current":-0.222294,"twenty":-0.344958,"median":-0.279367,"eighty":-0.209283,"marketCap":3468896},{"date":"2025-07-03","current":-0.240225,"twenty":-0.342139,"median":-0.277573,"eighty":-0.209588,"marketCap":3748716},{"date":"2025-07-11","current":-0.314762,"twenty":-0.339781,"median":-0.277296,"eighty":-0.209879,"marketCap":4911855},{"date":"2025-07-18","current":-0.242124,"twenty":-0.33814,"median":-0.276346,"eighty":-0.210021,"marketCap":3778350},{"date":"2025-07-25","current":-0.228831,"twenty":-0.337327,"median":-0.276269,"eighty":-0.210038,"marketCap":3570911},{"date":"2025-08-01","current":-0.243781,"twenty":-0.33696,"median":-0.274358,"eighty":-0.210831,"marketCap":3804205},{"date":"2025-08-08","current":-0.233576,"twenty":-0.336712,"median":-0.273838,"eighty":-0.212858,"marketCap":3644959},{"date":"2025-08-15","current":-0.231876,"twenty":-0.33606,"median":-0.271353,"eighty":-0.213354,"marketCap":3618418},{"date":"2025-08-22","current":-0.221928,"twenty":-0.335323,"median":-0.269787,"eighty":-0.212104,"marketCap":3535981},{"date":"2025-08-29","current":-0.23749,"twenty":-0.333566,"median":-0.269388,"eighty":-0.213354,"marketCap":3783930},{"date":"2025-09-05","current":-0.192157,"twenty":-0.332345,"median":-0.269014,"eighty":-0.213084,"marketCap":3061642},{"date":"2025-09-12","current":-0.207719,"twenty":-0.332042,"median":-0.268116,"eighty":-0.210012,"marketCap":3309592},{"date":"2025-09-19","current":-0.247639,"twenty":-0.331721,"median":-0.267958,"eighty":-0.20982,"marketCap":3945637},{"date":"2025-09-26","current":-0.362878,"twenty":-0.332345,"median":-0.267958,"eighty":-0.210012,"marketCap":5781732},{"date":"2025-10-03","current":-0.272683,"twenty":-0.334082,"median":-0.268394,"eighty":-0.210038,"marketCap":4344654},{"date":"2025-10-10","current":-0.24891,"twenty":-0.332345,"median":-0.268116,"eighty":-0.210567,"marketCap":3965889},{"date":"2025-10-17","current":-0.321134,"twenty":-0.33627,"median":-0.269014,"eighty":-0.211856,"marketCap":5116629},{"date":"2025-10-24","current":-0.188157,"twenty":-0.335429,"median":-0.268704,"eighty":-0.211856,"marketCap":2997912},{"date":"2025-10-31","current":-0.131167,"twenty":-0.334082,"median":-0.267958,"eighty":-0.20982,"marketCap":2089890},{"date":"2025-11-07","current":-0.105839,"twenty":-0.332345,"median":-0.267719,"eighty":-0.208727,"marketCap":1686325},{"date":"2025-11-14","current":-0.110362,"twenty":-0.332042,"median":-0.267321,"eighty":-0.207583,"marketCap":1758390},{"date":"2025-11-21","current":-0.081028,"twenty":-0.331721,"median":-0.26512,"eighty":-0.206427,"marketCap":1285354},{"date":"2025-11-28","current":-0.659255,"twenty":-0.334597,"median":-0.266863,"eighty":-0.206708,"marketCap":10457765},{"date":"2025-12-05","current":-0.720254,"twenty":-0.337177,"median":-0.26748,"eighty":-0.207472,"marketCap":11425396},{"date":"2025-12-12","current":-0.614194,"twenty":-0.34219,"median":-0.267958,"eighty":-0.207492,"marketCap":9742959},{"date":"2025-12-19","current":-0.474574,"twenty":-0.347254,"median":-0.268394,"eighty":-0.207537,"marketCap":7528174},{"date":"2025-12-26","current":-0.4608,"twenty":-0.349022,"median":-0.269014,"eighty":-0.207719,"marketCap":7309663},{"date":"2026-01-02","current":-0.447318,"twenty":-0.351152,"median":-0.26966,"eighty":-0.207719,"marketCap":7095801},{"date":"2026-01-09","current":-0.503223,"twenty":-0.354793,"median":-0.269873,"eighty":-0.208261,"marketCap":7982631},{"date":"2026-01-16","current":-0.526743,"twenty":-0.360917,"median":-0.271353,"eighty":-0.208641,"marketCap":8355727},{"date":"2026-01-23","current":-0.388481,"twenty":-0.368101,"median":-0.272683,"eighty":-0.20874,"marketCap":6162476},{"date":"2026-01-30","current":-0.377954,"twenty":-0.369864,"median":-0.273838,"eighty":-0.208765,"marketCap":5995491},{"date":"2026-02-06","current":-0.254616,"twenty":-0.369341,"median":-0.274166,"eighty":-0.209154,"marketCap":4038966},{"date":"2026-02-13","current":-0.250952,"twenty":-0.368944,"median":-0.274262,"eighty":-0.209588,"marketCap":3980851},{"date":"2026-02-20","current":-0.244846,"twenty":-0.368353,"median":-0.273838,"eighty":-0.20982,"marketCap":3883993},{"date":"2026-02-27","current":-0.219812,"twenty":-0.367557,"median":-0.272683,"eighty":-0.209529,"marketCap":3486877},{"date":"2026-03-06","current":-0.285756,"twenty":-0.365648,"median":-0.271783,"eighty":-0.20982,"marketCap":4532940},{"date":"2026-03-13","current":-0.266522,"twenty":-0.361898,"median":-0.272212,"eighty":-0.210012,"marketCap":4227838},{"date":"2026-03-20","current":-0.285756,"twenty":-0.360355,"median":-0.272267,"eighty":-0.210038,"marketCap":4532940},{"date":"2026-03-27","current":-0.254616,"twenty":-0.358486,"median":-0.271712,"eighty":-0.210567,"marketCap":4038966},{"date":"2026-04-02","current":-0.208821,"twenty":-0.355643,"median":-0.27114,"eighty":-0.210302,"marketCap":3312533},{"date":"2026-04-10","current":-0.260127,"twenty":-0.354839,"median":-0.269787,"eighty":-0.210302,"marketCap":5389056},{"date":"2026-04-17","current":-0.281981,"twenty":-0.354827,"median":-0.26986,"eighty":-0.211608,"marketCap":5841796},{"date":"2026-04-24","current":-0.268594,"twenty":-0.354771,"median":-0.270513,"eighty":-0.212842,"marketCap":5564456},{"date":"2026-05-01","current":-0.267882,"twenty":-0.354343,"median":-0.269886,"eighty":-0.213819,"marketCap":5549706},{"date":"2026-05-08","current":-0.295375,"twenty":-0.352599,"median":-0.271247,"eighty":-0.213857,"marketCap":6119281},{"date":"2026-05-15","current":-0.286915,"twenty":-0.351648,"median":-0.272111,"eighty":-0.213857,"marketCap":5944027},{"date":"2026-05-22","current":-0.634562,"twenty":-0.354827,"median":-0.272503,"eighty":-0.213857,"marketCap":13032642},{"date":"2026-05-29","current":-0.249501,"twenty":-0.354781,"median":-0.272503,"eighty":-0.213857,"marketCap":5124247},{"date":"2026-06-05","current":-0.248769,"twenty":-0.35473,"median":-0.272212,"eighty":-0.214067,"marketCap":5109220},{"date":"2026-06-12","current":-0.241452,"twenty":-0.352795,"median":-0.271911,"eighty":-0.214067,"marketCap":4958949},{"date":"2026-06-18","current":-0.230477,"twenty":-0.35201,"median":-0.271247,"eighty":-0.214405,"marketCap":4733542},{"date":"2026-06-26","current":-0.225356,"twenty":-0.351152,"median":-0.269886,"eighty":-0.214489,"marketCap":4628352},{"date":"2026-07-02","current":-0.229746,"twenty":-0.35011,"median":-0.269715,"eighty":-0.214549,"marketCap":4718515},{"date":"2026-07-10","current":-0.220234,"twenty":-0.349224,"median":-0.269201,"eighty":-0.214489,"marketCap":4523163},{"date":"2026-07-17","current":-0.207795,"twenty":-0.349022,"median":-0.268594,"eighty":-0.214067,"marketCap":4267702},{"date":"2026-07-24","current":-0.19682,"twenty":-0.348987,"median":-0.268161,"eighty":-0.213857,"marketCap":4042295},{"date":"2026-07-31","current":-0.20121,"twenty":-0.348468,"median":-0.267958,"eighty":-0.213493,"marketCap":4132458},{"date":"2026-08-07","current":-0.202674,"twenty":-0.34754,"median":-0.267882,"eighty":-0.210977,"marketCap":4162512},{"date":"2026-08-14","current":-0.245842,"twenty":-0.347244,"median":-0.2674,"eighty":-0.211398,"marketCap":5049112},{"date":"2026-08-21","current":-0.293824,"twenty":-0.347244,"median":-0.26748,"eighty":-0.210977,"marketCap":6506742}],"updateTime":1787489499394},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631630119","title":"Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631630119","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631630119?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:00","pubTimestamp":1777554000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April  30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284910/24675/en/Fate-Therapeutics-Announces-Data-Presentation-of-FT819-Off-the-Shelf-CAR-T-Cell-Product-Candidate-for-Systemic-Lupus-Erythematosus-SLE-at-the-CCR-East-2026-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CCR","BK4230","CAR","FATE","BK4139","SLE","BK4022","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631512824","title":"XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2631512824","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631512824?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:58","pubTimestamp":1777467480,"startTime":"0","endTime":"0","summary":"Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven Approved Phase 2a Human Clinical Trials Expect","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3283784/0/en/XTL-Biopharmaceuticals-to-Acquire-Psyga-Bio-Establishing-a-Leading-Psychedelic-Biotechnology-Platform-with-Advanced-Clinical-Pipeline-Licensed-GMP-Manufacturing-and-Proprietary-Psi.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","IE00B66KJ199.SGD","XTLB","IE0031619046.USD","BK4139","BK4157","BK4077","AEIS","LU1815336091.USD","IE00B7SZL793.SGD","SLE","XTL","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631116555","title":"InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2631116555","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631116555?lang=en_us&edition=fundamental","pubTime":"2026-04-29 08:37","pubTimestamp":1777423020,"startTime":"0","endTime":"0","summary":"BEIJING, April  28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3283360/0/en/InnoCare-Announces-First-Patient-Dosed-in-Phase-III-Trial-of-Orelabrutinib-for-SLE.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4134","III","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629837806","title":"InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2629837806","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629837806?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:20","pubTimestamp":1776950400,"startTime":"0","endTime":"0","summary":"BEIJING, April  23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3280053/0/en/InnoCare-Releases-2026-Q1-Results-Strong-Revenue-Growth-and-Sustained-Profitability.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1162221912.USD","LU1244550494.USD","LU2111349929.HKD","AD","LU0557290698.USD","LU0106831901.USD","LU0158827781.USD","LU0882574139.USD","LU1244550577.SGD","LU0320765646.SGD","LU0106261372.USD","LU0158827948.USD","BK4534","LU1074936037.SGD","LU1791710400.SGD","BK4077","IBD","LU0234570918.USD","LU2347655156.SGD","LU1732799900.SGD","LU0006306889.USD","BK4516","BK4504","LU1720051017.SGD","ITP","LU2271345857.HKD","BK4588","LU1732800096.USD","BK4585","LU1989772923.USD","LU0225283273.USD","LU2028103732.USD","LU2133065610.SGD","SLE","LU0314104364.USD","IE00BKVL7J92.USD","LU2089283258.USD","LU2357305700.SGD","BK4132","LU0971096721.USD","LU0795875169.SGD","LU1244550221.USD","LU2089284900.SGD","LU0528227936.USD","LU0912757837.SGD","BK4127","LU0795875086.SGD","BK4581","LU2023251221.USD","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628725523","title":"Press Release: Super League Issues Letter Encouraging Shareholders to Vote in Support of the Misfits Ads Division Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2628725523","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628725523?lang=en_us&edition=fundamental","pubTime":"2026-04-20 21:01","pubTimestamp":1776690060,"startTime":"0","endTime":"0","summary":"Transaction will add pro-forma profitable revenue, enhance predictability of financial performance, expand market share, and accelerate the Company's path to sustainable cash-based EBITDA profitability. Management encourages Shareholders to vote in favor of the proposal.SANTA MONICA, Calif., April 20, 2026  -- Super League  , an audience intelligence and media activation company trusted by global brands to reach and influence people who play video games across the digital landscape, issued a letter to shareholders from the Company's Chairman and Chief Executive Officer, Matt Edelman.We recently announced our agreement to acquire the Misfits Ads Division. Already generating profitable revenue, integrating the division is fully expected to improve the predictability of our performance, expand our market share, and accelerate our path to cash-based EBITDA profitability. We believe it is an important step and ideal opportunity for Super League to build sustainable operating momentum and sh","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627842912","title":"Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2627842912","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627842912?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:30","pubTimestamp":1776256200,"startTime":"0","endTime":"0","summary":"Study Highlights Dagger Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in Pre-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274436/0/en/Allogene-Therapeutics-Announces-Nature-Communications-Publication-Highlighting-Pre-Clinical-Data-for-ALLO-329-a-Next-Generation-Dual-Targeted-CD19-CD70-Allogeneic-CAR-T-for-Autoimm.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLO","BK4077","BK4230","SLE","BK4139","BK4505","CAR","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626187969","title":"Super League Acquires Stake in Top Roblox Experience, My Avatar!","url":"https://stock-news.laohu8.com/highlight/detail?id=2626187969","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626187969?lang=en_us&edition=fundamental","pubTime":"2026-04-09 21:00","pubTimestamp":1775739606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA9YP7SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625949158","title":"Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625949158","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625949158?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:00","pubTimestamp":1775646000,"startTime":"0","endTime":"0","summary":"WELLESLEY HILLS, Mass., April  08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/08/3269976/0/en/Climb-Bio-to-Host-R-D-Spotlight-Webcast-Highlighting-Budoprutug-and-the-CD19-Opportunity-on-May-5-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4077","BK4585","SLE","BK4218","HST","BK4181","BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623878835","title":"Super League Enterprise price target lowered to $15 from $60 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2623878835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623878835?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:30","pubTimestamp":1774963805,"startTime":"0","endTime":"0","summary":"Maxim lowered the firm’s price target on Super League Enterprise (SLE) to $15 from $60 and keeps a Buy rating on the shares. The firm is adjusting ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-price-target-lowered-to-15-from-60-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-price-target-lowered-to-15-from-60-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589931","title":"3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589931","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589931?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:13","pubTimestamp":1774959180,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc.  today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with both quantitative and qualitative growth: annual revenue hit RMB 17.7 billion, a historic breakthrough past the RMB 10 billion mark, representing a 94.3% year-on-year  increase; net profit attributable to shareholders of the parent company reached RMB 8.48 billion, surging 305.8% YoY; adjusted net profit attributable to shareholders of the parent company stood at RMB 8.45 billion, a 264.6% YoY rise. The company's profitability achieved a leap-forward growth, demonstrating robust growth momentum.Under the collaboration agreement, 3SBio granted Pfizer exclusive global development and commercialization rights to SSGJ-707, with the total potential deal value exceeding US$6 billion. The company is also entitled to tiered double-digi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/3sbio-announces-2025-annual-results-dual-engines-of-innovative-rd-and-global-collaboration-propel-revenue-past-rmb-10-billion-milestone-302729335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999003800.SGD","IND.AU","LU1894683264.USD","SG9999001176.USD","BK4007","IBD","SG9999013999.USD","BK7095","SG9999002232.USD","BK4581","CLDT","IE00B19Z3581.USD","IND","LU0321505439.SGD","BK4534","LU0225284248.USD","LU0170899867.USD","BK4588","LU0456855351.SGD","BK4592","BK4568","IE00BLSP4452.SGD","ITP","BRVO","BK1583","LU1894683348.USD","LU0321505868.SGD","LU0985481810.HKD","ADA.AU","PFE","01530","BK1161","SAA","BK7016","IE0002270589.USD","IE00B19Z3B42.SGD","BK4077","BK4585","SLE","BK4181","LU0306806265.USD","LU1883839398.USD","BK1593","LU1066053197.SGD","LU0289739699.SGD","BK4599","HK0000165453.HKD","IE000M9KFDE8.USD","BK4218","SG9999011175.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623865317","title":"Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623865317","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623865317?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:01","pubTimestamp":1774872060,"startTime":"0","endTime":"0","summary":"First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjgren’s disease $75 million private placement strengthens balance sheet and supports telitacicep","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264589/0/en/Vor-Bio-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317889","title":"Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317889","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317889?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872000,"startTime":"0","endTime":"0","summary":"First and only dual BAFF/APRIL inhibitor in primary Sjgren’s disease, one of the largest autoimmune diseases without an approved therapyBOSTON, March  30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264556/0/en/Vor-Bio-Doses-First-Patient-in-Global-Phase-3-UPSTREAM-SjD-Registrational-Trial-of-Telitacicept-in-Primary-Sj%C3%B6gren-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315283","title":"InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315283","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315283?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:48","pubTimestamp":1774864080,"startTime":"0","endTime":"0","summary":"The innovative drugmaker's newfound profitability marks its transition into a new stage characterized by stability and virtuous development cycles. Despite attracting strong market attention for its big business development deals, the company remains relatively undervalued. InnoCare now stands at a \"triple inflection point,\" with profitability achieved, globalization enhanced, and core pipelines progressed, marking a new stage in its development.InnoCare also differs from some of its peers that achieved early profitability by relying on one-time upfront payments from partnerships. By comparison, InnoCare's march to profitability has been jointly propelled by a dual engine of licensing deals and direct product sales. On the commercial front, the company's drug sales reached 1.44 billion yuan last year, up 43.4%.Orelabrutinib continued its strong momentum, now included on China's National Reimbursement Drug List for all four of its indications. Its approval as a first-line treatment for ","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/30/-30-3-2026-101148-thebambooworks-com.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/30/-30-3-2026-101148-thebambooworks-com.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/26/03/51532367/innocare-hits-profit-milestone-relative-undervaluation-points-to-stock-upside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/26/03/51532367/innocare-hits-profit-milestone-relative-undervaluation-points-to-stock-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1791710582.SGD","LU1989772923.USD","BK4585","LU1074936037.SGD","LU1244550577.SGD","LU1363072403.SGD","LU1732800096.USD","LU0314104364.USD","LU0912757837.SGD","BK4504","LU1162221912.USD","LU1244550221.USD","LU1244550494.USD","LU1720051108.HKD","LU0006306889.USD","LU2028103732.USD","LU1720051017.SGD","LU2133065610.SGD","LU0098860793.USD","LU2023251221.USD","LU0320765646.SGD","LU0158827781.USD","LU1989772840.SGD","BK4077","BK4516","LU2089283258.USD","LU0971096721.USD","LU2111349929.HKD","LU2347655156.SGD","BK4122","PCOM","SLE","LU0106261372.USD","ITP","LU1791710400.SGD","LU0557290698.USD","LU0267386448.USD","LU2357305700.SGD","LU1548497426.USD","LU1668664300.SGD","LU0882574139.USD","BK4199","BK4534","LU0795875169.SGD","LU0795875086.SGD","LU2089284900.SGD","BK4581","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622179822","title":"Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622179822","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622179822?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:31","pubTimestamp":1774618272,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc reports results for the quarter ended December 31 - Earnings SummarySuper League Enterprise Inc SLE.OQ reported a quarterly adjusted loss of $9.44 per share for the quarter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F179:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622825603","title":"Super League FY2025 net loss widens 24.51% to $20.7 million; revenue drops 29.91% to $11.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622825603","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622825603?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:31","pubTimestamp":1774611088,"startTime":"0","endTime":"0","summary":"Super League published an earnings press release reporting fourth-quarter and full-year 2025 financial results.Q4 revenue was USD 3.2 million, down 6.6%.FY revenue was USD 11.3 million, down 29.9%.Super League ended 2025 with USD 14.4 million in cash and cash equivalents and said it was debt-free, while CEO Matt Edelman said cash basis EBITDA profitability is targeted by year-end.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL4R3048:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","BK4112","BK4077","SLE","SG9999014039.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622984825","title":"Press Release: Super League Reports Fourth Quarter and Full Year 2025 Financial Results, Completes Business Transformation and Advances Path to Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2622984825","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622984825?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:30","pubTimestamp":1774611000,"startTime":"0","endTime":"0","summary":"Q4 2025 Delivers Strongest Revenue Quarter of the Year. Debt-Free Balance Sheet and $14M in Year-End Cash Enable Focus on Execution. Diversified Revenue and Shift to Scalable Offerings Support Path to Profitable Future. SANTA MONICA, March 27, 2026  --  Super League  , an audience intelligence and media activation company that generates revenue by executing interactive advertising and immersive content programs for brands seeking to reach and influence people who play video games, today released fourth quarter and full year 2025 financial results.Super League Chief Executive Officer, Matt Edelman Commented:. \"Super League is a fundamentally different company than it was a year ago. We have a stronger foundation and a clearer path to scale, positioned to help brands reach and influence one of the most valuable and under-monetized consumer segments in modern media and culture--the gamer demographic.Combined with our recently announced agreement to acquire the Misfits Ads Division, subjec","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622076334","title":"Super League Enterprise Inc  expected to post a loss of $3.28 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622076334","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622076334?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:44","pubTimestamp":1774442649,"startTime":"0","endTime":"0","summary":"Super League Enterprise Inc  expected to post a loss of $3.28 a share - Earnings Preview Super League Enterprise Inc SLE.OQ SLE.O is expected to  show a rise in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D1DV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621756263","title":"Super League to buy Misfits Ads Division for USD 1.5 million and 19.99% equity stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2621756263","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621756263?lang=en_us&edition=fundamental","pubTime":"2026-03-21 03:12","pubTimestamp":1774033948,"startTime":"0","endTime":"0","summary":"Super League entered a definitive agreement to acquire the Misfits Ads Division from Misfits Gaming Group, with closing subject to certain conditions including Super League shareholder approval.Consideration includes USD 1.5 million in cash and 19.99% of the aggregate of Super League common shares outstanding plus shares underlying certain pre-funded warrants from the October 2025 PIPE financing.Misfits may receive additional cash and equity over the 24 months after closing if specified net revenue milestones are met.Misfits will also receive a warrant to purchase Super League common stock with an exercise price of USD 18 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Super League Enterprise Inc. published the original conte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL8svjyD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620276193","title":"Press Release: Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276193","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276193?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:05","pubTimestamp":1773950700,"startTime":"0","endTime":"0","summary":"-- Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis  --. -- Plan to submit NDA for envudeucitinib in PsO in 2H 2026 --. -- Potentially pivotal Phase 2b clinical topline data for envudeucitinib in systemic lupus erythematosus  anticipated 3Q 2026 --. \"Alumis concluded a pivotal year marked by strong execution and the Phase 3 clinical validation of envudeucitinib in moderate-to-severe plaque psoriasis, underscoring the promise of TYK2 inhibition and envudeucitinib's highly differentiated clinical profile,\" said Martin Babler, President and Chief Executive Officer of Alumis. \"By maximally inhibiting TYK2 to block both IL-23 and IL-17 pathways, envudeucitinib delivered comprehensive disease control with rapid onset of action, high rates of skin clearance, and meaningful symptom improvements in our Phase 3 ONWARD program that reinforce our","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","CNS","KOL","BK4007","ALMS","BK4077","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620590253","title":"Super League to acquire Misfits Ads Division for USD 1.5 million and 19.99% equity stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2620590253","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620590253?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:05","pubTimestamp":1773835536,"startTime":"0","endTime":"0","summary":"Super League entered a definitive agreement to acquire the Misfits Ads Division from Misfits Gaming Group. Misfits will receive USD 1.5 million in cash and 19.99% of Super League’s fully issued and outstanding common shares plus shares underlying certain pre-funded warrants from an October 2025 PIPE financing. Misfits may receive additional cash and equity over 24 months after closing tied to specified net revenue milestones. Misfits will also receive a warrant to buy Super League common stock at an exercise price of USD 18 per share, and a Misfits board member is expected to join Super League’s board after completion.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6HrWmP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4077","SLE","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014039.USD","BK4588","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014021.USD","BK4112","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":112,"code":"91000000","status":"200"}]}}